The Dementia Therapeutics Innovation Initiative (DTII) is a new initiative at the University of British Columbia led by the distinguished investigators Dr. Haakon Nygaard, Dr. Brian MacVicar, and Dr. Freda Miller.
Our vision
A future where Alzheimer’s therapeutics are discovered, developed, and tested right here at UBC.
Our mission
To accelerate novel therapeutic development in Alzheimer’s disease and other dementias by leveraging the assets within UBC’s rapidly expanding ecosystem.
Our goals
1. Identify target genes, proteins, and pathways implicated in Alzheimer’s.
2. Discover and develop new drugs that can effectively engage these pathways leading to new therapies for Alzheimer’s.